by Alex Kadhim
In a recent study, researchers from the University of California, San Francisco, have demonstrated that high exposure to melphalan significantly increases the risk of graft-versus-host disease...
by Cancer Immunology, Immunotherapy
Scientists believe prostaglandin F2 receptor negative regulator (PTGFRN) is a possible target for chimeric antigen receptor (CAR) T-cell therapy in patients with glioblastoma (GBM).
by Randy Taplitz, MD, FIDSA
Non-Aspergillus invasive mold infections (NAIMIs) are rare but often life-threatening complications for stem cell transplant recipients. A new ASTCT clinical practice guideline outlines best...
by Alex Kadhim
In a recent study published in The Journal of Immunology, researchers from Ohio State University have demonstrated that inhibition of dihydroorotate dehydrogenase (DHODH) selectively modulates T...
by Blood Advances
Researchers report the safety of a novel approach to insulate edited cells from chimeric antigen receptor (CAR) selection and attack.
by ASTCT Talks
In a special co-branded episode between Oncology On theGo hosted by CancerNetwork® and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks, Nora...